Clinical Perspectives

Distant Margins Following Pelvic Exenteration Improve the Survival Rate for Women with Gynecologic Cancer

A study shows patients with distant margins following pelvic exenteration have improved the overall survival rate by 111 months when compared to...

Q&A with Dr. Michael Vogelbaum on Stereotactic Radiosurgery for Brain Tumors

Stereotactic radiosurgery is a non-invasive treatment that is delivered with the highest precision, like a neurosurgical procedure, but without an...

Gynecologic Cancer Genetics and Molecular Medicine Tumor Board at Moffitt Cancer Center

We offer a highly collaborative Gynecologic Cancer Genetics and Molecular Medicine Tumor Board to ensure that each patient is provided with a...

Q&A: Dr. Alice Yu Discusses Management of Localized Prostate Cancer Using Irreversible Electroporation Ablation

Moffitt's Dr. Alice Yu discusses the different treatment options for localized prostate cancer, including focal therapy, an FDA-approved treatment.

Q&A: Dr. Yamoah Shares His Vision for Moffitt To Become Global Epicenter for Precision Radiotherapy

The new chair of the Department of Radiation Oncology, Dr. Kosj Yamoah, shares his vision for the department and hopes for Moffitt to be the leader...

Fluorescent Imaging Technology Now Available At Moffitt For Ovarian Cancer Surgery

The U.S. Food and Drug Administration (FDA) recently approved CYTALUX for adult patients with ovarian cancer as an adjunct for intraoperative...

Some Cancer Symptoms More Likely to Present in Emergency Rooms

Emergency room providers are increasingly diagnosing cancer symptoms in patients. It is important that ER providers refer these patients to a cancer...

Understanding Chronic Myelogenous Leukemia (CML)

Chronic myeloid leukemia often doesn’t produce noticeable symptoms in its early stages. In fact, many patients don’t realize there is a problem until...

Refining Multiple Myeloma Treatments: the EMMA Created at Moffitt

A result of Mark Pentecost’s generous donation, the EMMA database tests a multiple myeloma patient’s sensitivity to dozens of drugs at one time to...

Immune Checkpoint Inhibitor Targeting LAG3 May Lead to Therapeutic Approaches in Advanced Melanoma

Moffitt researchers have become the first in the world to visualize the molecular structure of the LAG3 protein. Their findings reveal several...

Research Presented on Baseline Metastatic Patterns and Clinical Outcomes Among BRAF-Positive Metastatic Melanoma Patients

Dr. Zeynep Eroglu shares her research findings evaluating the association between baseline metastatic patterns and outcomes among BRAF+ metastatic...

11-Gene Expression Signature May Predict Sentinel Lymph Node Metastatic Status in Melanoma Patients

Dr. Ahmad Tarhini, a medical oncologist in the Cutaneous Oncology Department, shares research findings looking at biomarkers derived from primary...

Advancements in Treatment for Breast and Gynecologic Cancers

Gynecologic Oncology Program Chair Dr. Robert Wenham presents treatment advancements using antibody-drug conjugates (ADCs) in HER2-positive breast...

Moffitt Researcher Receives Grant to Study Immunogenic Activity of Oncolytic Virus and Immune Checkpoint Blockade

Dr. Roger Li, a genitourinary oncology surgeon at Moffitt Cancer Center, received a grant from the Department of Defense to study the immunogenic...

Cellular Immunotherapy Highlights from ASCO

Moffitt’s physicians and scientists were proud to share and present their cellular immunotherapy research findings at American Society of Clinical...